Evidence map›Paper›PMID 26549854›Full record

ArticleNeuropharmacology2016

Linalool reverses neuropathological and behavioral impairments in old triple transgenic Alzheimer's mice.

Angélica Maria Sabogal-Guáqueta, Edison Osorio, Gloria Patricia Cardona-Gómez

Abstract read
In one paragraph

Article in Neuropharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Open medicine (Warsaw, Poland) · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Angélica Maria Sabogal-GuáquetaNeuroscience Group of Antioquia, Cellular and Molecular Neurobiology Area - School of Medicine, SIU, University of Antioquia UdeA, Calle 70 No, 52-21, Medellin, Colombia.
Edison OsorioGrupo de Investigación en Sustancias Bioactivas, Facultad de Ciencias Farmacéuticas y Alimentarias, Universidad de Antioquía UdeA, Calle 70 No, 52-21, Medellin, Colombia.
Gloria Patricia Cardona-GómezNeuroscience Group of Antioquia, Cellular and Molecular Neurobiology Area - School of Medicine, SIU, University of Antioquia UdeA, Calle 70 No, 52-21, Medellin, Colombia. Electronic address: patricia.cardonag@udea.edu.co.
Universidad de Antioquia · CO

Funding

Development of RNAi as Treatment for NeurodegenerationR01AG029802 · NIA · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI KOSIK, KENNETH STEPHEN · 2007 to 2011
$674k
NIA NIH HHS 1 R01 AG029802-01NIA NIH HHS R01 AG029802
6 · The paper itself

Abstract

Alzheimer's disease (AD) is an age-related progressive neurodegenerative disorder. Several types of treatments have been tested to block or delay the onset of the disease, but none have been completely successful. Diet, lifestyle and natural products are currently the main scientific focuses. Here, we evaluate the effects of oral administration of the monoterpene linalool (25 mg/kg), every 48 h for 3 months, on aged (21-24 months old) mice with a triple transgenic model of AD (3xTg-AD) mice. Linalool-treated 3xTg-AD mice showed improved learning and spatial memory and greater risk assessment behavior during the elevated plus maze. Hippocampi and amygdalae from linalool-treated 3xTg-AD mice exhibited a significant reduction in extracellular β-amyloidosis, tauopathy, astrogliosis and microgliosis as well as a significant reduction in the levels of the pro-inflammatory markers p38 MAPK, NOS2, COX2 and IL-1β. Together, our findings suggest that linalool reverses the histopathological hallmarks of AD and restores cognitive and emotional functions via an anti-inflammatory effect. Thus, linalool may be an AD prevention candidate for preclinical studies.

Indexed as

Acyclic MonoterpenesAlzheimer DiseaseAmyloid beta-PeptidesAnimalsBehavior, AnimalBrainDisease Models, AnimalMaze LearningMiceMice, TransgenicMonoterpenesSpatial Memorytau ProteinsAcyclic MonoterpenesAmyloid beta-PeptideslinaloolMonoterpenestau ProteinsAlzheimer's diseaseBehavior functionInflammationLinalool

Identifiers

PMID26549854
PMCPMC4698173
OpenAlexW2170522615

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.